Fish oil and other nutritional adjuvants for treatment of congestive heart failure

Medical Hypotheses

Volumn 46, Issue 4, 1996, Pages 400-406

  McCarty, M F ^a  

^a Nutrition 21 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FISH OIL;

CONGESTIVE HEART FAILURE; DIET SUPPLEMENTATION; DRUG EFFECT; HUMAN; HYPOTHESIS; NUTRITION; PRIORITY JOURNAL; REVIEW;

EID: 0029924540     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(96)90194-2     Document Type: Article

References (120)

1. Persson S. Symposium on the endocrinology of cardiac failure. Pathophysiologic aspects - hemodynamics. Acta Medica Scand 1986; Suppl 707: 7-14.
2. Dyckner T, Wester P-O. Salt and water balance in congestive heart failure. Acta Medica Scand 1986; Suppl 707: 27-31.
3. Wester P O, Dyckner T. Intracellular electrolytes in cardiac failure. Acta Medica Scand 1986; Suppl 707: 33-36.
4. Francis G S. Interaction of the sympathetic nervous system and electrolytes in congestive heart failure. Am J Cardiol 1990; 65: 24E-27E.
5. Packer M. Potential role of potassium as a determinant of morbidity and mortality in patients with systemic hypertension and congestive heart failure. Am J Cardiol 1990; 65: 45E-51E.
6. Weber K T, Brilla C G. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-1865.
7. Re R N. Myocardial hypertrophy, angiotensin, and ACE inhibitors. Angiology 1993; 44: 875-881.
8. Pfeffer M A, Braunwald E. Ventricular remodeling after myocardial infarction. Circulation 1990; 81: 1161-1172.
9. Schaffer S W, Punna S, Duan J et al. Mechanism underlying physiological modulation of myocardial contraction by taurine. In: Lombardini J B, Schaffer S W, Azuma J, eds. Taurine. New York: Plenum Press, 1992: 193-198.
10. Schaffer S W, Ballard C, Azuma J. Mechanisms underlying physiological and pharmacological actions of taurine on myocardial calcium transport. In: Huxtable R, Michalk D V, eds. Taurine in Health and Disease. New York: Plenum Press, 1994: 171-180.
11. Read W O, Welty J D. Effect of taurine on epinephrine and digoxin-induced irregularities of the dog heart. J Pharmacol Exp Ther 1963; 139: 283-289.
12. Chazov E T, Malchikova L S, Lipina N V et al. Taurine and electrical activity of the heart. Circ Res 1974; 34 and 35(SuPppl III): 11-12.
13. Wang G X, Duan J, Zhou S et al. Antiarrhythmic action of taurine. In: Lombardini J B et al, eds. Taurine. New York: Plenum Press, 1992: 187-192.
14. Azuma J and the Heart Failure Research with Taurine Group. Long-term effect of taurine in congestive heart failure: preliminary report. In: Huxtable R, Michalk D V, eds. Taurine in Health and Disease. New York: Plenum Press, 1994: 425-433.
15. Ristori M T, Verdetti J. Effects of taurine on rat aorta in vitro. Fund Clin Pharmacol 1991; 5: 245-258.
16. Franconi F, Giotti A, Manzini S et al. The effect of taurine on high potassium- and noradrenaline-induced contraction in rabbit ear artery. Br J Pharm 1982; 75: 605-612.
17. Yamaguchi A, Kanda Sh, Amano H et al. Jap J Geriatr 1967; 4: 96.
18. Kohashi N, Okabayashi T, Hama J, Katori R. Decreased urinary taurine in essential hypertension. In: Kuriyama K, Huxtable R J, Iwata H, eds. Sulfur Amino Acids: Biochemical and Clinical Aspects. New York: Alan R. Liss, 1983: 73-87.
19. Fujita T, Ando K, Noda H et al. Effects of increased adrenomedullary activity and taurine in young patients with borderline hypertension. Circulation 1983; 75: 525-532.
20. Nara Y, Yamori Y, Lovenberg W. Effect of dietary taurine on blood pressure in spontaneously hypertensive rats. Biochem Pharmacol 1978; 27: 2689-2692.
21. Inoue A, Takahashi H, Lee L-C et al. Retardation of the development of hypertension in DOCA salt rats by taurine supplement. Cardiovasc Res 1988; 22: 351-358.
22. Nakagawa M, Takeda K, Yoshitomi T et al. Antihypertensive effect of taurine on salt-induced hypertension. In: Huxtable R, Michalk D V, eds. Taurine in Health and Disease. New York: Plenum Press, 1994: 197-206.
23. Meldrum M J, Tu R, Patterson T et al. The effect of taurine on blood pressure, and urinary sodium, potassium and calcium excretion. In: Huxtable R, Michalk D V, eds. Taurine in Health and Disease. New York: Plenum Press, 1994: 207-215.
24. Azuma J, Sawamura A, Awata N et al. Double-blind randomized cross-over trial of taurine in congestive heart failure. Curr Ther Res 1983; 34: 543-557.
25. Azuma J, Sawamura A, Awata N. Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn Circ J 1992; 56: 95-99.
26. Takihara K, Azuma J, Awata N et al. Beneficial effect of taurine in rabbits with chronic congestive heart failure. Am Heart J 1986; 112: 1278-1284.
27. 10. Proc Natl Acad Sci 1985; 82: 901-904.
28. Lenaz G, Fato R, Castelluccio C et al. The function of coenzyme Q in mitochondria. Clin Invest 1993; 71: S66-S70.
29. 10. In: Lenaz, G, ed. Coenzyme Q. Biochemistry, Bioenergetics, and Clinical Applications of Ubiquinone. New York: Wiley-Interscience, 1985: 479-507.
30. 10. Proc Natl Acad Sci 1985; 82: 4240-4244.
31. 10 therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1990; 65: 521-523.
32. 10: A new drug for cardiovascular disease. J Clin Pharmacol 1990; 30: 596-608.
33. 10 (Ubiquinone). Clin Invest 1993; 71: S116-S123.
34. 10 as an adjuvant therapy in heart failure. Clin Invest 1993; 71: S129-133.
35. 10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clin Invest 1993; 71: S134-S136.
36. 10 as adjunctive therapy in heart failure (interim analysis). Clin Invest 1993; 71: S145-S149.
37. Folts J D, Shug A L, Koke J R, Bittar N. Protection of the ischemic dog myocardium with carnitine. Am J Cardiol 1978; 41: 1209-1214.
38. Cerretelli P, Marconi C. L-carnitine supplementation in humans. The effects on physical performance. Int J Sports Med 1990; 11: 1-14.
39. Kobayashi A, Fujisawa S. Effect of L-carnitine on mitochondrial acyl coA esters in the ischemic dog heart. J Mol Cell Cardiol 1994; 26: 499-508.
40. Cherchi A, Lai C, Angelino F et al. Effects of L-carnitine on exercise tolerance in chronic stable angina: a multi-center, double-blind, randomized, placebo controlled crossover study. Int J Clin Pharm Ther Toxicol 1985; 23: 569-574.
41. Brevetti G, Chiariello M, Ferulano G et al. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation 1988; 77: 767-773.
42. Regitz V, Shug A L, Fleck E. Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases. Am J Cardiol 1990; 65: 755-760.
43. Ghidini O, Azzurro M, Vita G, Sartori G. Evaluation of the therapeutic efficacy of L-carnitine in congestive heart failure. Int J Clin Pharm Ther Toxicol 1988; 26: 217-220.
44. Ferro M, Crivello R, Gianotti A, Conti M. Trattamento della cardiomiopatia dilatativa con carnitina e beta-bloccanti in associazione. Clin Ther 1993; 143: 109-113.
45. Whitmer J T. L-carnitine treatment improves cardiac performance and restores high-energy phosphate pools in cardiomyopathic Syrian hamster. Circ Res 1987; 61: 396-408.
46. Altura B M, Altura B T, Gebrewold A. Magnesium deficiency and hypertension: correlation between magnesium-deficient diets and microcirculatory changes in situ. Science 1984; 223: 1315-1317.
47. McCarty M F. Complementary vascular-protective actions of magnesium and taurine - a rationale for magnesium taurate. Med Hypotheses 1995; 46: 77-80.
48. Allison S P, Morley C J, Burns-Cox C J. Insulin, glucose, and potassium in the treatment of congestive heart failure. Br Med J 1972; 3: 675-678.
49. Majid P A, Meeran M K M, Sharma B, Taylor S H. Insulin and glucose in the treatment of heart-failure. Lancet 1972; ii: 937-941.
50. Muller J E, Mochizuki S, Koster J K Jr et al. Insulin therapy for depressed myocardial contractility after prolonged ischemia. Am J Cardiol 1978; 41: 1215-1221.
51. Reikeras O, Gunnes P, Sørlie D et al. Haemodynamic effects of high doses of insulin during acute left ventricular failure in dogs. Eur Heart J 1985; 6: 451-457.
52. Opie L H. Metabolism of free fatty acids, glucose and catecholamines in acute myocardial infarction. Relation to myocardial ischemia and infarct size. Am J Cardiol 1975; 36: 938-953.
53. Alexander W D, Oake R J. The effect of insulin on vascular reactivity to norepinephrine. Diabetes 1977; 26: 611-614.
54. Mathias C J, Da Costa D F, Fosbraey P et al. Hypotensive and sedative effects of insulin in autonomic failure. Br Med J 1987; 295: 161-163.
55. Laakso M, Edelman S V, Brechtel G, Baron A D. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest 1990; 85: 1844-1852.
56. Baron A D, Brechtel-Hook G, Johnson A, Hardin D. Skeletal muscle blood flow. A possible link between insulin resistance and blood pressure. Hypertension 1993; 21: 129-135.
57. Rowe J W, Young J B, Minaker K L et al. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 1981; 30: 219-225.
58. Gans ROB, Donker AJM. Insulin and blood pressure regulation. J Int Med 1991; 229(Suppl 2): 49-64.
59. Lipsitz L A, Nyquist R P Jr, Wei J Y, Rowe J W. Postprandial reduction in blood pressure in the elderly. N Engl J Med 1983; 309: 81-83.
60. Modan M, Halkin H, Almog S et al. Hyperinsulinemia. A link between hypertension, obesity and glucose intolerance. J Clin Invest 1985; 75: 809-817.
61. Ferrannini E, Buzzigoli G, Bonadonna R et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-357.
62. Shen D-C, Schieh S-M, Fuh MM-T et al. Resistance to insulin-stimulated-glucose uptake in patients with hypertension. J Clin Endocrinol Metabol 1988; 66: 580-583.
63. Evans G W. The effect of chromium picolinate on insulin controlled parameters in humans. Int J Biosoc Med Res 1989; 11: 163-180.
64. Evans G W, Pouchnik D J. Composition and biological activity of chromium-pyridine carboxylate complexes. J Inorg Biochem 1993; 49: 177-187.
65. Amoiken E K, Southern L L, Fernandez J M et al. Effect of chromium as chromium tripicolinate on glucose tolerance, insulin sensitivity and plasma metabolites in pigs. J Animal Sci 1993; 71(Suppl 1): 176.
66. Lindemann M D, Wood C M, Harper A F et al. Dietary chromium picolinate additions improve gain:feed and carcass characteristics in growing-finishing pigs and increase litter size in reproducing sows. J Animal Sci 1995; 73: 457-465.
67. 2+]i). FASEB J 1995; 9: A615.
68. Morris G S, Guidry K A, Hegsted M, Hasten D L. Effects of dietary chromium supplementation on cardiac mass, metabolic enzymes, and contractile-proteins. Nutr Res 1995; 15: 1045-1052.
69. Alpert N R, Mulieri L A, Litten R Z. Functional significance of altered myosin adenosine triphosphatase activity in enlarged hearts. Am J Cardiol 1979; 44: 947-953.
70. Alpert N R, Mulieri L A. Increased myothermal economy of isometric force generation in compensated cardiac hypertrophy induced by pulmonary artery constriction in the rabbit. Circ Res 1982; 50: 491-500.
71. Wikman-Coffelt J, Sievers R, Parmley W W. Influence of myocardial isomyosins on cardiac performance and oxygen consumption. Biochem Biophys Res Comm 1985; 130: 1314-1323.
72. Fitzsimons D P, Bodell P W, Herrick R E, Baldwin K M. Left ventricular functional capacity in the endurance-trained rodent. J Appl Physiol 1990; 69: 305-312.
73. Morris G S, Fitzsimons D P, Baldwin K M, Barnard R J. Exercise capacity of rats remains unaffected by a chronic pressure overload. Cardiovasc Res 1993; 27: 1346-1349.
74. Morris G S, Surdyka D G, Haddad F, Baldwin K M. Apparent influence of metabolism on cardiac isomyosin profile of food-restricted rats. Am J Physiol 1990; 258: R346-R351.
75. Dillmann W H. Diabetes mellitus induces changes in cardiac myosin of the rat. Diabetes 1980; 29: 579-582.
76. Katz A M. The myocardium in congestive heart failure. Am J Cardiol 1989; 63: 12A-16A.
77. Knapp H R, Fitzgerald G A. The antihypertensive effects of fish oil: a controlled study of polyusaturated fatty acid supplements in essential hypertension. N Engl J Med 1989; 320: 1037-1043.
78. Bønaa K H, Bjerve K S, Straume B et al. Effect of eicosapentaenoic and docosahexaenoic acids on blood pressure in hypertension. N Engl J Med 1990; 322: 795-801.
79. Kenny D, Warliter D C, Pleuss J A et al. Effect of omega-3 fatty acids on the vascular response to angiotensin in normotensive men. Am J Cardiol 1992; 70: 1347-1352.
80. Chin J P F, Gust A P, Nestel P J, Dart A M. Marine oils dose-dependently inhibit vasoconstriction of forearm resistance vessels in humans. Hypertension 1993; 21: 22-28.
81. Locher R, Sachinidis A, Steiner A et al. Fish oil affects phosphoinositol turnover and thromboxane A metabolism in cultured vascular muscle cells. Biochim Biophys Acta 1989; 1012: 279-283.
82. Hui R, Robillard M, Falardeau P. Inhibition of vasopressin-induced formation of diradylglycerols in vascular smooth muscle cells by incorporation of eicosapentaenoic acid in membrane phospholipids. J Hypertens 1992; 10: 1145-1153.
83. q. Science 1991; 251: 804-807.
84. q class of G proteins. Nature 1991; 350: 516-518.
85. McCarty M F. Fish oil may impede tumor angiogenesis and invasiveness by down-regulating protein kinase C and modulating eicosanoid production. Med Hypotheses 1995; 46: 107-115.
86. Medini L, Colli S, Mosconi C et al. Diets rich in n-9, n-6 and n-3 fatty acids differentially affect the generation of inositol phosphates and of thromboxane by stimulated platelets, in the rabbit. Biochem Pharm 1990; 39: 129-133.
87. Chetty N, Vickers J D, Kinlough-Rathbone R L et al. EPA inhibits inositol phosphate formation in U46619-stimulated rabbit platelets. FASEB J 1988; 2: A1163.
88. Tang W, Ziboh V A, Isseroff R R. Evidence of inositol phospholipid turnover in guinea pig epidermis: suppression of inositol triphosphate generation in animals supplemented with fish oil diet. J Invest Dermatol 1987; 88: 521.
89. Reibel D K, Holahan M A, Hock C E. Effects of dietary fish oil on cardiac responsiveness to adrenoceptor stimulation. Am J Physiol 1988; 254: H494-H499.
90. Terano T, Hirai A, Hamazaki T et al. Effect of oral administration of highly purified eicosapentaenoic acid on platelet function, blood viscosity and red cell deformability in healthy human subjects. Atherosclerosis 1983; 46: 321-331.
91. Cartwright I J, Pockley A G, Galloway J H et al. The effects of dietary ω-3 polyunsaturated fatty acids on erythrocyte membrane phospholipids, erythrocyte deformability and blood viscosity in healthy volunteers. Atherosclerosis 1985; 55: 267-281.
92. Mills D E, Galey W F, Dixon H. Effects of dietary fatty-acid supplementation on fatty-acid composition and deformability of young and old erythrocytes. Biochim Biophys Acta 1993; 1149: 313-318.
93. Høstmark A T, Bjerkedal T, Kierulf P et al. Fish oil and plasma fibrinogen. Br Med J 1988; 297: 180-181.
94. Radack K, Deck C, Huster G. Dietary supplementation with low-dose fish oils lowers fibrinogen levels: a randomized, double-blind controlled study. Ann Intern Med 1989; 111: 757-758.
95. Saynor R, Gillott T. Changes in blood lipids and fibrinogen with a note on safety in a long term study on the effects of n-3 fatty acids in subjects receiving fish oil supplements and followed for seven years. Lipids 1992; 27: 533-538.
96. Rogers S, James K S, Butland B K et al. Effects of fish oil supplement on serum lipids, blood pressure, bleeding time, hemostatic and rheological variables. A double blind randomised controlled trial on healthy volunteers. Atherosclerosis 1987; 63: 137-143.
97. McLennan P L, Abeywardena M Y, Charnock J S. A comparison of the long-term effects of n-3 and n-6 polyun-saturated fatty acid dietary supplements and the action of indomethacin upon the mechanical performance and susceptibility of the rat heart to dysrhythmia. Prost Leuko Med 1987; 27: 183-195.
98. McLennan P L, Abeywardena M Y, Charnock J S. Dietary fish oil prevents ventricular fibrillation following coronary artery occlusion and reperfusion. Am Heart J 1988; 116: 709-717.
99. Riemersma R A, Sargent C A. Dietary fish oil and ischaemic arrhythmias. J Intern Med 1989; 225(Suppl 1): 111-116.
100. Charnock J S, McLennan P L, Sundram K, Abeywardena M Y. Omega-3 PUFA's reduce the vulnerability of the rat heart to ischaemic arrhythmia in the presence of a high intake of saturated animal fat. Nutr Res 1991; 11: 1025-1034.
101. McLennan P L. Relative effects of dietary saturated, monounsaturated, and polyunsaturated fatty acids on cardiac arrhythmias in rats. Am J Clin Nutr 1993; 57: 207-212.
102. Charnock J S. Antiarrhythmic effects of fish oils. In: Simopoulos A P, Kifer R R, Martin R E, Barlow S M, eds. Health Effects of ω3 Polyunsaturated Fatty Acids in Seafoods. World Rev Nutr Diet, Basel: Karger, 1991, vol. 66: 278-291.
103. Parratt J R, Coker S J, Wainwright C L. Eicosanoids and susceptibility to ventricular arrhythmias during myocardial ischaemia and reperfusion. J Mol Cell Cardiol 1987; 19(Suppl V): 55-66.
104. Sheridan D J, Penkoski P A, Sobel B E. Alpha adrenergic contributions to dysrhythmia during myocardial ischemia and reperfusion in cats. J Clin Invest 1980; 65: 161-171.
105. Hallaq H, Sellmayer A, Smith T W, Leaf A. Protective effects of eicosapentaenoic acid on ouabain toxicity in neonatal rat cardiac myocytes. Proc Natl Acad Sci 1990; 87: 7834-7838.
106. Patten G S, Rinaldi J A, McMurchie E J. Effects of dietary eicosapentaenoate (20:5 n-3) on cardiac beta-adrenergic receptor activity in the marmoset monkey. Biochem Biophys Res Comm 1989; 162: 686-693.
107. Bristow M R, Ginsburg R, Minobe W et al. Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N Engl J Med 1982; 307: 205-211.
108. Sadoshima J, Izumo S. Signal transduction pathways of angiotensin II-induced c-fos gene expression in cardiac myocytes in vitro. Roles of phospholipid-derived second messengers. Circ Res 1993; 73: 424-438.
109. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429-1435.
110. The SOLVD Investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure . N Engl J Med 1991; 325: 293-302.
111. Konstam M A, Rousseau M F, Kronenberg M W et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation 1992; 86: 431-438.
112. Dzau V J. Vascular renin-angiotensin system and vascular protection. J Cardiovasc Pharm 1993; 22(Suppl 5): S1-S9.
113. Goodnight S H. The effects of n-3 fatty acids on atherosclerosis and the vascular response to injury. Arch Pathol Lab Med 1993; 117: 102-106.
114. Goodnight S H, Cairns J A, Fisher M, FitzGerald G A. Assessment of the therapeutic use of n-3 fatty acids in vascular disease and thrombosis. Chest 1992; 102: 374S-384S.
115. Gapinski J P, VanRuiswyk J V, Heudenbert G R, Schectman G S. Preventing restenosis with fish oils following coronary angioplasty. A meta-analysis. Arch Intern Med 1993; 153: 1595-1601.
116. Dyerberg J, Bang H O, Stofferson E. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis. Lancet 1978; ii: 117-119.
117. Goodnight S H Jr, Harris W S, Connor W E. The effects of dietary ω3 fatty acids on platelet composition and function in man: a prospective, controlled study. Blood 1981; 58: 880-885.
118. Thorngren M, Gustafson A. Effects of 11-week increase in dietary eicosapentaenoic acid on bleeding time, lipids, and platelet aggregation. Lancet 1981; ii: 1190-1193.
119. Hay C R, Durber A P, Saynor R. Effect of fish oil on platelet kinetics in patients with ischemic heart disease. Lancet 1982; i: 1269-1270.
120. Knapp H R, Reilly I A, Allesandrini P, FitzGerald G A. In vivo indexes of platelet and vascular function during fish-oil administration in patients with atherosclerosis. N Engl J Med 1986; 314: 937-947.